Literature DB >> 11577061

Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects?

I Bjarnason1, K D Rainsford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11577061      PMCID： PMC1071578          DOI： 10.1136/ewjm.175.4.267

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  10 in total

1.  Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

Authors:  P Brooks; P Emery; J F Evans; H Fenner; C J Hawkey; C Patrono; J Smolen; F Breedveld; R Day; M Dougados; E W Ehrich; J Gijon-Baños; T K Kvien; M H Van Rijswijk; T Warner; H Zeidler
Journal:  Rheumatology (Oxford)       Date:  1999-08       Impact factor: 7.580

Review 2.  Non steroidal anti-inflammatory drugs, cyclooxygenase selectivity and gastrointestinal toxicity.

Authors:  M Jacob; R Simpson; I Bjarnason
Journal:  Ital J Gastroenterol Hepatol       Date:  1998-02

3.  Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats.

Authors:  F Karmeli; P Cohen; D Rachmilewitz
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-02       Impact factor: 2.566

4.  Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.

Authors:  B K Reuter; S Asfaha; A Buret; K A Sharkey; J L Wallace
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

5.  Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Authors:  L S Simon; A L Weaver; D Y Graham; A J Kivitz; P E Lipsky; R C Hubbard; P C Isakson; K M Verburg; S S Yu; W W Zhao; G S Geis
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

6.  Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.

Authors:  F L Lanza; M F Rack; T J Simon; H Quan; J A Bolognese; M E Hoover; F R Wilson; S E Harper
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

7.  COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.

Authors:  G Sigthorsson; R Crane; T Simon; M Hoover; H Quan; J Bolognese; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

8.  Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.

Authors:  G W Cannon; J R Caldwell; P Holt; B McLean; B Seidenberg; J Bolognese; E Ehrich; S Mukhopadhyay; B Daniels
Journal:  Arthritis Rheum       Date:  2000-05

9.  Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.

Authors:  A A Shah; B Thjodleifsson; F E Murray; E Kay; M Barry; G Sigthorsson; H Gudjonsson; E Oddsson; A B Price; D J Fitzgerald; I Bjarnason
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 10.  Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.

Authors:  I Bjarnason; J Hayllar; A J MacPherson; A S Russell
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682
  10 in total
  2 in total

1.  The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase.

Authors:  Shamsher S Saini; Deborah L Gessell-Lee; Johnny W Peterson
Journal:  Inflammation       Date:  2003-04       Impact factor: 4.092

Review 2.  Raging the War Against Inflammation With Natural Products.

Authors:  Ali Attiq; Juriyati Jalil; Khairana Husain; Waqas Ahmad
Journal:  Front Pharmacol       Date:  2018-09-07       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.